B. Brett Finlay Microbiologist
Brett Finlay‘s research explores the interaction between pathogenic bacteria, such as Salmonella and E. Coli, and their host cells. He is particularly interested by how the microbiome of humans can affect conditions such as asthma, inflammatory bowel disease, food allergies, and cardiovascular disease. He is also interested in treatment and prevention of infections, such as the C. difficile bacteria, and was the leader of the successful initiative to develop a SARS vaccine in 2003.
Officer of Canada
Order of BC
Fellow of the Royal Society of Canada
Fellow of the Canadian Academy of Health Sciences
CIHR Distinguished Investigator
I.I. Ivanov et al, "Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine," Cell Host Microbe, vol. 4, no. 4, pp. 337-349, 2008.
I. Sekirov et al, "Gut microbiota in health and disease," Physiol. Rev., vol. 90, no. 3, pp. 859-904, 2010.
M.A. Croxen and B.B. Finlay, Molecular mechanisms of Escherichia coli pathogenicity, Nat. Rev. Microbiol., vol. 8, no. 1, pp. 26-38, 2010.
C. Lupp et al, "Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of enterobacteriaceae," Cell Host Microbe, vol. 2, no. 2, pp. 119-129, 2007.
Program Co-Director Humans & the Microbiome
Senior Fellow Humans & the Microbiome
University of British Columbia
PhD (Biochemistry) University of Alberta
BSc Honours (Biochemistry) University of Alberta
Ideas Related to B. Brett Finlay
CIFAR’s four new programs are having their first collaborative meetings, delving into questions such as how to improve solar energy, define the complexities of human consciousness, and improve health through a better understanding of microbes and the molecular basis of life.